Could Molnupiravir Be the First-Line Alternative Oral Antiviral Agent for COVID-19 Patients at High Risk?

J Korean Med Sci. 2024 Feb 19;39(6):e74. doi: 10.3346/jkms.2024.39.e74.NO ABSTRACTPMID:38374633 | PMC:PMC10876427 | DOI:10.3346/jkms.2024.39.e74

Source: Journal of Korean Medical Science - February 20, 2024 Category: Biomedical Science Authors: Ji Yong Lee Source Type: research